A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Subjects

Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs GDC 0853 (Primary)
  • Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 14 Aug 2017 Status changed from recruiting to completed.
    • 20 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top